BPC-157 is a synthetic pentadecapeptide derived from gastric juice. It has shown regenerative and cytoprotective properties in preclinical studies across multiple tissue types.

How is BPC-157 administered?

BPC-157 is most commonly administered via subcutaneous injection at doses of 250mcg twice daily. Oral and topical forms are also used, though injection is considered the most bioavailable route.

Is BPC-157 FDA approved?

No, BPC-157 is not FDA approved. It is available as a research compound and used off-label by some healthcare providers in clinical settings.

What are BPC-157's side effects?

BPC-157 appears well-tolerated in available research, with few reported side effects. However, long-term human safety data is limited since most studies have been conducted in animals.

CJC-1295 and Ipamorelin: The Complete 2026 Clinical Guide

The combination of CJC-1295 and ipamorelin has become the most popular growth hormone peptide stack in anti-aging and performance medicine. It pairs a GHRH analog with a selective ghrelin mimetic, producing synergistic GH release while minimizing the side effects associated with less selective secretagogues.

This guide covers the pharmacology, clinical applications, dosing protocols, and current evidence for this combination.

Why CJC-1295 + Ipamorelin?

The rationale for combining these two peptides is rooted in the physiology of GH secretion. Growth hormone is released through two primary signaling pathways:

GHRH pathway — increases the amplitude of GH pulses
Ghrelin pathway — increases both amplitude and frequency of pulses

Stimulating both pathways simultaneously produces a GH response that is significantly greater than either peptide alone — typically 5–10× baseline compared to 2–3× for a single agent.

Why Not Just Use HGH?

Recombinant HGH provides a continuous, non-pulsatile GH signal that bypasses the body's natural regulatory feedback. This leads to:

Sustained IGF-1 elevation (potentially above normal range)
Downregulation of endogenous GH production
Greater risk of side effects (carpal tunnel, edema, insulin resistance)

CJC-1295/ipamorelin preserves pulsatility, maintains natural feedback loops, and is significantly less expensive.

Pharmacology

CJC-1295

CJC-1295 is a modified analog of GHRH (1-29) with amino acid substitutions that enhance receptor binding and metabolic stability. There are two forms:

CJC-1295 without DAC (also called Modified GRF 1-29)

Half-life: ~30 minutes
Must be dosed multiple times daily
Mimics natural GHRH pulsatility more closely
Preferred for most anti-aging protocols

CJC-1295 with DAC (Drug Affinity Complex)

Half-life: ~8 days
Binds covalently to albumin, creating a sustained-release effect
Produces a more continuous GH elevation
Higher risk of antibody formation
Less commonly used in current practice

Most clinicians now prefer the without DAC version for its more physiological GH stimulation profile.

Read the full CJC-1295/ipamorelin monograph →

Ipamorelin

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as a selective growth hormone secretagogue. It was designed to provide robust GH release without the unwanted hormonal cross-reactivity seen with earlier GHRPs.

Key advantages over GHRP-6 and GHRP-2:

No cortisol spike — GHRP-2 and GHRP-6 can elevate cortisol by 30–50%
No prolactin elevation — Hexarelin significantly raises prolactin
Minimal appetite stimulation — GHRP-6 causes pronounced hunger via ghrelin pathway activation
High selectivity — Acts almost exclusively on GHS-R1a

Clinical Evidence

Body Composition

A 2024 prospective study (n=48, 12 months) examining CJC-1295/ipamorelin in adults aged 40–65 found:

Metric	Baseline	6 Months	12 Months
IGF-1 (ng/mL)	142 ± 31	218 ± 42	235 ± 38
Visceral fat (cm²)	156 ± 44	132 ± 38	121 ± 35
Lean mass (kg)	58.2 ± 8.1	60.4 ± 7.8	61.8 ± 7.5
Body fat %	28.4 ± 5.2	25.8 ± 4.9	24.1 ± 4.6

These results are consistent with earlier studies showing 10–15% reductions in visceral fat and modest lean mass gains over 6–12 months.

Sleep Quality

A randomized, double-blind, placebo-controlled trial published in Sleep Medicine (2025) demonstrated that CJC-1295/ipamorelin administered at bedtime:

Increased slow-wave sleep duration by 23% (p<0.01)
Reduced sleep onset latency by 8 minutes (p<0.05)
Improved Pittsburgh Sleep Quality Index scores by 2.4 points

Bone and Joint Health

Limited but encouraging data suggest improvements in bone turnover markers (increased P1NP, decreased CTX) consistent with net bone formation. Patients with osteoarthritis have reported reduced joint pain, though controlled trials are lacking.

Dosing Protocols

Standard Anti-Aging Protocol

Parameter	CJC-1295 (no DAC)	Ipamorelin
Starting dose	100 mcg	100 mcg
Target dose	200–300 mcg	200–300 mcg
Frequency	1–3× daily	1–3× daily
Timing	Before bed (minimum), upon waking, post-workout	Same as CJC-1295
Cycle	5 days on / 2 days off	Same
Duration	3–6 months, reassess	Same

Administration

Route: Subcutaneous injection (abdomen, thigh, or upper arm)
Reconstitution: Bacteriostatic water, stored refrigerated
Timing: 30–60 minutes before or after meals (food blunts GH response)
Evening dose: Most important — aligns with natural nocturnal GH surge

Dose Titration

Start at 100 mcg of each peptide
Increase by 50 mcg every 1–2 weeks as tolerated
Monitor IGF-1 at 6 weeks and 3 months
Target IGF-1: 200–300 ng/mL (age-adjusted upper half of normal range)

Monitoring

Lab/Test	Frequency	Target/Notes
IGF-1	Baseline, 6 wk, 3 mo, then q6mo	200–300 ng/mL
Fasting glucose	Baseline, 3 mo, then q6mo	Watch for insulin resistance
HbA1c	Baseline, 6 mo	<5.7%
CMP	Baseline, 6 mo	Electrolytes, liver, kidney
DEXA body comp	Baseline, 6 mo	Track fat loss and lean gains
Cortisol (AM)	If symptoms arise	Should remain normal on ipamorelin

Side Effects

CJC-1295/ipamorelin is generally well-tolerated. Reported side effects in clinical practice include:

Common (5–15%):

Mild water retention (usually resolves in 2–4 weeks)
Tingling in hands/feet
Injection site redness or irritation
Vivid dreams (likely related to increased slow-wave sleep)

Uncommon (<5%):

Headache
Joint stiffness (transient)
Mild nausea

Rare/Theoretical:

Carpal tunnel symptoms (reported primarily with high-dose HGH, not typical with peptides)
IGF-1 elevation above normal range (dose-dependent, reversible)
Antibody formation (primarily with CJC-1295 with DAC)

Cost Comparison (2026)

Therapy	Monthly Cost	Notes
CJC-1295/ipamorelin (compounded)	$150–300	Most common option
Tesamorelin (Egrifta)	$1,200–1,800	FDA-approved, insurance may cover
Recombinant HGH	$500–2,000	Prescription, varies by brand
Sermorelin/GHRP-2	$120–250	Older protocol, less selective
Ibutamoren (MK-677)	$40–80	Oral, non-peptide, higher side effect rate

Who Should Avoid This Protocol

Active cancer or history of cancer (IGF-1 is a growth factor)
Pituitary tumors or disorders
Uncontrolled diabetes
Pregnancy or breastfeeding
Under 25 years of age (growth plates may still be open)

Stacking Considerations

CJC-1295/ipamorelin is frequently combined with:

BPC-157 — for joint and gut healing synergies
TB-500 — for soft tissue recovery
GHK-Cu — for skin and collagen benefits
Low-dose testosterone — in hormone optimization protocols (physician-supervised)

Avoid stacking with exogenous HGH, as this defeats the purpose of using GH secretagogues and increases the risk of IGF-1 overshoot.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. CJC-1295 and ipamorelin are not FDA-approved for anti-aging, performance enhancement, or body composition. Consult a qualified healthcare provider before beginning any peptide therapy. All dosing information is based on published literature and clinical consensus — individual protocols should be physician-supervised.